COMPARATIVE CONTROLLED STUDY OF ANTIHYPERTENSIVE EFFICACY AND SAFETY OF CARVEDILOL IN PATIENTS WITH HYPERTENSION AND OBESITY OR DIABETES 2 TYPE (BASED ON RESULTS OF MULTICENTER TRIAL ACCORD)

Aim. To study efficacy and safety of beta-blocker with vasodilating properties carvedilol (Acridilole, Akrihin, Russia) as a part of the combined therapy of patients with arterial hypertension (HT) and diabetes mellitus 2 type (DM2) and/or obesity.

Material and methods. 592 patients: 176 men (29,7%) and 416 women (70,3%) with HT were examined. 194 patients had D2 and 398 patients had obesity. Patients were randomized for carvedilol therapy (n=291) or control group (n=301). Carvedilol was prescribed additionally to current therapy in dose of 6,25 mg BID, in 2 weeks the dose was increased to 12,5 mg BID if it was necessary. Blood pressure (BP) and heart rate, number of angina attacks were registered at visits. ECG, laboratory analysis (plasma lipide profile, serum glucose, glycolised haemoglobin, serum K+ and Na+), evaluation of depression and anxiety status (according to special questionnaires) were performed on the first and the last visits.

Results. 582 patients completed the study. 7 patients dropped out from carvedilol group and 3 patients - from control group. The levels of systolic BP (SBP) and diastolic BP (DBP) were decreased during study, more significantly in carvedilol group (р<0,0001). SBP decreased on 24,8 mm Hg in patients of carvedilol group and on 21,4 mm Hg in patients of control group. DBP decreased on 12,5 mm Hg and 11 mm Hg respectively. Angina attacks were registered less often in patients of carvedilol group (р=0,001). Serum glucose and lipid spectrum did not change in both groups. Depression level decreased in patients receiving carvedilol. 17 side effects were registered in carvedilol group and 15 - in control group (р=0,575)

Conclusion. High antihypertensive efficacy of carvedilol is confirmed in hypertensive patients with DM2 and/or obesity. Good tolerability and metabolic neutrality of carvedilol is also observed.

1. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика 2008; 7(6 приложение):3-32.

2. ESC guidelines desk reference. Compendium of abridged ESC guidelines 2008. London, UK: Lippincott Williams & Wilkins, 2008. pp.15-33

3. Напалков Д.А. Карведилол — перспективный бета-адреноблокатор нового поколения. Медицинские новости 2008;(11):66-70

4. Метелица В.И. Справочник по клинической фармакологии сердечно- сосудистых лекарственных средств. М.:МИА; 2005.

5. Sponer G., Bartch W., Strein K. et al. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive property. J Cardiovasc Pharmacol 1987;9(3):317-27.

6. Shuetze G.E., Sabin G.V., Janitzki I., Scherhag A. Treatment of essential hypertension with Carvedilol: Results of the open-lable prospective trial in more than 10 000 patients [in German]. Perfusion 2003;16(12):424-9.

7. Кобалава Ж.Д., Котовская Ю.В., Соколова М.А. и др. Эффективность и переносимость карведилола при лечении среднетяжёлой эссенциальной гипертонии. Кардиология 1998;(2):52-6.

8. Мычка В.Б., Чазова И.Е. Применение карведилола у больных с мета- болическим синдромом. Системные гипертензии 2005,7(2):25-6.

9. Чихладзе Н.М., Чазова И.Е. Возможности применения бета-адрено- блокаторов с вазодилатирующими свойствами у больных с артериальной гипертонией. Consilium medicum 2004;6(2):39-41.

10. Stienen U., Meyer-Sabellek W. Hemodynamic and metabolic effects of carvedilol: a meta-analysis approach. Clin Investig 1992;70 Suppl 1:S65- 72.

11. Праскурничий Е.А., Шевченко О.П., Макарова С.В. Влияние карведилола на выраженность гипертензивной реакции, возникающей в условиях стресс-тестирования у больных артериальной гипертензией. Кардиоваскулярная терапия и профилактика 2004;(5):10-7.

12. Bakris G.L., Fonseca V., Katholi R.E. et al.; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292(18):2227-36.

13. Jacob S., Rett K., Wicklmayr M. et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996;14(4):489-94.

14. Maggi E., Marchesi E., Covini D. et al. Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 1996;27(4):532-8.

15. Мордовин В.Ф., Белокопытова Н.В., Фальковская А.Ю., Ефимова И.Ю. Гипотензивная эффективность и церебропротективные свойства карведилола у больных артериальной гипертонией, ассоциированной с сахарным диабетом 2 типа. Кардиология 2007;(10):31-6.